Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Lymphoma, Infection, Leukemia
Interventions: Fluconazole, Voriconazole; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more

Conditions: Healthy Participants
Interventions: Influenza virus vaccine, Vitamins A and D, Placebo; Biological · Dietary Supplement · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 8 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV Infections, Anti-Infective Agents
Interventions: No intervention (not applicable); Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Human Immunodeficiency Virus, Depression, Mental Health
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Vascular Graft Infection
Interventions: Prophylactic muscle flap; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections, HIV Primary Infection
Interventions: CHIP, Control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 4,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more

Conditions: Clostridioides Difficile Infection
Interventions: LMN-201, Placebo; Drug
Lead sponsor: Lumen Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more

Conditions: Invasive Mould Infection
Interventions: EL219, Active Comparator- IV Antifungal (LAmB or voriconazole); Drug
Lead sponsor: Elion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more

Conditions: Sexually Transmitted Infection (STI) Prevention, Unintended Pregnancy Prevention, Sexual Risk Reduction, Alcohol and Other Substance Use Prevention, Intimate Partner Violence Prevention
Interventions: Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits; Behavioral
Lead sponsor: United States Department of Defense; Federal
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Transplantation, Infection, Cytomegalovirus Infections
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more

Conditions: Staphylococcus Aureus
Interventions: CA-MRSA Decolonization; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Female only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: SARS-CoV-2 Infection
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,475 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Kidney Trasplant
Interventions: Valganciclovir; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mental Health Issue, Hiv, Substance Use
Interventions: Single Session Narrative Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10,577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Foster City, California

Conditions: HIV Infections
Interventions: Digital Health Companion (mobile App); Behavioral
Lead sponsor: WV Health Right, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: HIV, HIV Infections
Interventions: Be Proud! Be Responsible!, Becoming A Responsible Teen (BART), Reducing the Risk; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years to 60 Years
Enrollment: 901 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Malaria
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2,101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Covid-19, SARS-CoV2
Interventions: BIO101, Placebo; Drug
Lead sponsor: Biophytis; Industry
Eligibility: 45 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • Irvine, California • Natchitoches, Louisiana + 3 more

Conditions: Urinary Tract Infections
Interventions: Cranberry juice cocktail; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Influenza, Infections, Pneumococcal
Interventions: Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Search by objective public record fields.

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

Acceptability Study of Vaginal Films for HIV Prevention

Addressing Psychosocial Comorbidities in HIV Treatment and Prevention

Prophylactic Muscle Flaps in Vascular Surgery

A Couples-based Intervention for Transgender Women and Their Partners

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

LMN-201 for Prevention of C. Difficile Infection Recurrence

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

Preventing Health Damaging Behaviors in Male and Female Army Recruits

Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

Walk-in Therapy in Low Barrier Primary Care

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Training Community Members to Deliver HIV Prevention Programs to Urban Youth

Malaria Clinical Trials Center General Screening

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients

Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts